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Papillary thyroid carcinoma (PTC) accounts for over 80% of all thyroid malignancies. The molecular pathogenesis remains
incompletely clariﬁed although activation of the RET fusion oncogenes, and RAS and BRAF oncogenes, has been well
characterized. Novel technologies using genome-wide approaches to study tumor genomes and epigenomes have provided
great insights into tumor development. Growing evidence shows that acquired epigenetic abnormalities participate with genetic
alterations to cause altered patterns of gene expression/function. It has been established beyond doubt that promoter cytosine
methylation in CpG islands, and the subsequent gene silencing, is intimately involved in cancer development. These epigenetic
events very likely contribute to signiﬁcant variation in gene expression proﬁling, phenotypic features, and biologic characteristics
seen in PTC. Hypermethylation of promoter regions has also been analyzed in PTC, and most studies have focused on individual
genes or a small cohort of genes implicated in tumorigenesis.
1.Background
Thyroid carcinoma is the most common endocrine malig-
nancy. Papillary thyroid cancer (PTC) accounts for over
90% of thyroid malignancies [1]. With improved diagnostic
techniques, papillary thyroid carcinoma is identiﬁed much
more frequently than in the past [2]. Currently, ways to
preoperatively identify patients with invasive thyroid cancer
include asymptomatic disease with concomitant vocal cord
dysfunction or subglottic/tracheal mass, recurrent disease in
the central compartment, symptomatic disease with voice
changes, dyspnea, hemoptysis, or dysphagia, and ﬁnally
documented invasive disease based on preoperative imag-
ing [3]. More papillary thyroid cancers are diagnosed as
microcarcinomas; therefore, molecular methods of detecting
aggressive disease will aid in treatment planning.
The majority of genetic alterations in thyroid cancer
exert their oncogenic actions at least partially through the
activation of the MAP kinase/ERK pathway. Constitutive
activation of the MAP kinase/ERK pathway leads to tumori-
genesis by upregulating cell division and proliferation [4].
Activation of this pathway is a common and important
mechanisminthegenesisandprogressionofhumancancers.
Whenconstitutivelyactivated,theMAPkinasepathwayleads
to tumorigenesis [4]. Alterations of RET/PTC, BRAF, and
RAS genes are linked to papillary thyroid tumorigenesis.
RET proto-oncogene encodes a cell membrane receptor
tyrosine kinase. Ligands of the kinase are of the glial-
cell line-derived neurotrophic factor (GDNF) family which
cause the receptors to dimerize upon binding, leading to
autophosphorylation of tyrosine residues and initiation of
the MAP kinase/ERK pathway signaling cascade [5]. High
expression of RET in parafollicular C-cells of the thyroid
gland is consistent with its role in the development of
neural crest-derived cell lineages. This high expression of
RET does not normally occur in thyroid follicular cells;2 Journal of Thyroid Research
however, RET activation in these cells occurs by fusion of the
3’ tyrosine domain of RET to the 5’ portion of constitutively
expressed genes. The most common RET/PTC rearrange-
ments seen in PTC are RET/PTC1 (fusion with H4 gene)
and RET/PTC3 (fusion with NCOA4 gene). Prevalence of
RET/PTC rearrangements in PTC is greatest in populations
exposed to radiation (60–70%). In the general population,
the prevalence is higher in children [6]. Activation of
RET/PTC results in downregulation of thyroglobulin and
sodium iodide importer genes, which are thyroid speciﬁc,
and thyroid follicular cell diﬀerentiation. Wild-type and
truncatedformsofRET/PTCactivatethePI3K/AKTpathway
leading to tumorigenesis [6, 7].
Mutations of BRAF, a serine-threonine kinase and down-
streamsignalingmoleculeofRASandRET,arepotentactiva-
tors of the MAP kinase/ERK pathway [4, 8]. These missense
mutations of the BRAF gene, located on chromosome 7,
occur in the kinase domain with the T1799A transversion
mutation that results in a single amino acid substitution of
valine to glutamic acid (V600E) accounting for 80–90% of
BRAF activating mutations [6, 9]. The V600E mutation is
thought to mimic phosphorylation in the activation segment
of BRAF by inserting a negatively charged residue adjacent to
an activating phosphorylation site [4].
BRAF V600E occurs as a sporadic mutation in thyroid
cancer [9, 10] and is restricted to papillary and anaplastic
or poorly diﬀerentiated carcinomas [11]. Prevalence of the
mutation is reported in papillary thyroid cancer at 35–
40%, with a signiﬁcantly higher prevalence in males than
females [9]. The rate of BRAF mutation in PTC is the second
highest to that in melanomas (60%) and is much higher than
other cancers such as colorectal adenocarcinomas (5–10%)
and lung cancers (1.8%) [9]. BRAF V600E correlates with
poorer clinicopathologic outcomes deﬁned as extrathyroidal
extension, lymph node metastasis, and advanced tumor
grade (III/IV) at presentation and is prognostic of tumor
recurrence [12–15].
Activating mutations of the three RAS oncogenes (H-
RAS, K-RAS, and N-RAS) occur in thyroid tumors; however,
their prevalence depending on histology of the tumors has
been controversial [16]. Early studies demonstrated that
RAS mutations were more frequent in follicular tumors
than papillary thyroid cancers, in addition to diﬀerent
patterns of mutations occurring in the two types. Indeed,
mutations in up to 50% on microfollicular adenoma further
supported the idea that RAS oncogene activation was an
early event in follicular thyroid tumorigenesis. More recent
studies have reported varying incidences of RAS mutations
in thyroid tumors (0–50% in PTC, 0–85% in adenomas, 14–
62% in FTC, and 0–60% in anaplastic carcinomas). Some
investigators ﬁnd no correlation between RAS mutation
isoforms and tumor pathology, while others report a higher
frequency of mutations in codon61 of H-RAS and N-RAS in
FTC and poorly diﬀerentiated carcinomas.
Although not conﬁrmed by similar studies [10], 38% of
BRAF-positive papillary thyroid tumors showed RET/PTC
rearrangement [9], contrary to reports that BRAF V600E
mutationdoesnotoccurwithRET/PTCorRASmutationsin
cancer [10]. Concurrent RET/PTC and BRAF mutations has
also recently been reported in papillary thyroid cancer [17].
The low oncogenic potential of both BRAF and RET/PTC1
suggest that both mutations occurring in the same path-
way are not necessarily redundant but may cooperate in
papillary thyroid tumorigenesis. Indeed, RET/PTC1 and
RAS mutations have been shown to synergistically lead to
tumorigenesis [9].
The molecular pathogenesis of PTC thus remains incom-
pletely clariﬁed. With respect to gene alterations, papillary
thyroid cancers have relatively low rates of loss of het-
erozygosity, with no speciﬁc region displaying a particularly
high prevalence when compared to follicular thyroid cancers
[18]. Like RET, BRAF, or RAS mutations, other molecular
alterations are thought to be essential for the induction
of papillary thyroid cancer. Epigenetic events very likely
contribute to signiﬁcant variation in gene expression proﬁl-
ing, phenotypical features, and biologic characteristics seen
among papillary thyroid carcinoma [19].
2.Epigenetics MechanismsInvolved
in Tumorigenesis
Epigenetic silencing of regulatory genes is part of the global
genomic alterations in cancer that alter pathways relevant
to stem-cell growth and diﬀerentiation. Epigenetic silencing
mechanisms include covalent modiﬁcations of chromatin,
DNA cytosine methylation, noncoding RNAs, and nucleo-
some remodeling [20]. It has been proposed that epigenetic
abnormalities may play a seminal role in the earliest steps
in tumorigenesis [21–24]. Epigenetic changes may act in
concert with genetic changes resulting in tumorigenesis,
because they are mitotically heritable. The high degree of
mitotic stability of silencing plus the progressive nature by
which it is achieved makes pathological silencing of growth
controlling and other genes essential to carcinogenesis.
Patterns of DNA methylation are linked to gene
expression; for example, methylation in a gene promoter
region generally correlates with a silenced gene [25]. DNA
methylation, the DNA methyltransferase (DNMT) catalyzed
addition of methyl group to cytosine ring, is restricted to
cytosines that precede a guanosine in the DNA sequence (the
CpG dinucleotide) in humans and other mammals [25]. The
distributionofCpGdinucleotidesinthegenomeisunusually
asymmetric, occurring in small clusters called “CpG islands”.
The CpG islands are often in promoter regions of genes and
are usually unmethylated regardless of the transcriptional
state.ThishighlightstheimportanceofDNAmethylationfor
gene expression, especially in transcriptional silencing [25].
Aberrant DNA methylation plays a strong role in
tumorigenesis. Global hypomethylation of intergenic CpG
dinucleotides and regional hypermethylation of CpG islands
in promoter regions are characteristic hallmarks of many
cancers [24]. The impact of hypermethylation on tumori-
genesis is further illustrated by the silencing of multiple
tumor suppressor genes, thereby contributing to the hall-
marks of carcinogenesis which include evading apoptosis
(P53, p14ARF, BNIP3 and Caspase-8), insensitivity to anti-
growth signals (p16INK4a and miR-124a), sustained angio-
genesis (TIMP3 and TSP1), limitless replicative potentialJournal of Thyroid Research 3
(hTERT), and tissue invasion and metastasis (E-cadherin
and LIMS2).
Transcriptional silencing is also a result of chromatin
compaction due to convergence of DNA methylation and
histone modiﬁcations. Methylated DNA recruits methyl-
bindingproteins(MBDPs),whichhavemethyl-CpG-binding
domains (MBD), to hypermethylated DNA. MBDPs asso-
ciate with histone deacetylases, resulting in chromatin
remodeling and gene silencing. In addition to these mecha-
nismsofsilencing,histonemethyltransferase(HMTs)repress
transcription by methylation of lysine 9 of histone 3 (H3K9)
or lysine 27 of histone 3 (H3K27). An excellent review
of epigenetic modiﬁcations of chromatin is provided by
Iacobuzio-Donahue [26].
The inﬂuence of epigenetic events on tumorigenesis
is well illustrated by the evolution of colon cancer, in
which risk factors for common cancers such as aging and
inﬂammation are shown to cause expansions in either
normal colon epithelial stem cells or precursor cells derived
from them. Epigenetic gatekeepers such as cyclin-dependent
kinaseinhibitor2A(CDKN2A/p16),secretedfrizzled-related
protein (SFRP), GATA-binding protein 4 and 5 (GATA-4
and -5), and adenomatous polyposis of the colon (APC)
prevent early tumor progression in colon cancer. Normal
epigenetic modulation of these gatekeeper genes allows them
topreventstem/precursorcellsfrombecomingimmortalized
during periods of chronic stresses and renewal pressures on
cell systems. APC is a classically mutated tumor suppressor
gene in colon cancer, which is also inactivated by epigenetic
mechanisms [27]. Epigenetic silencing of one allele serves as
a second-hit in Knudson’s hypothesis for tumor suppressor
gene inactivation when paired which mutations on the other
allele [21].
Like APC, loss of p16 can be epigenetically mediated,
permitting expanding cells to develop genomic instability
[28, 29] and further epigenetic gene-silencing events [30].
Its loss is seen in subsets of preinvasive stages of colon and
other cancers [30]. Finally, GATA-4 and -5 transcription
factor genes, important for both embryonic gastrointestinal
epithelial development and for maturation in adults, are
epigenetically silenced in about half of all the preinvasive
and invasive lesions for colon cancer [31]. This can hamper
diﬀerentiation and promote precursor cell expansion.
The wingless-type MMTV integration site (Wnt) path-
way activation also illustrates how multiple epigenetic events
may act in concert to aﬀect a single-cell pathway. Inappro-
priate silencing of these genes leads to abnormal activation
of the Wnt pathway, which plays a canonical role in colon
tumorigenesis [23]. These genes are independently aﬀected
by epigenetic events but result in Wnt activation. Four genes
in the SFRP family encoding proteins that antagonize the
action of the Wnt ligand at the cell membrane are hyperme-
thylatedsimultaneouslyinthemajorityofpreinvasivelesions
for colon cancer. Upregulation of the survival protein Sirtuin
1 (SIRT1) also results in Wnt pathway activation. SIRT1 is
upregulated as a result of loss of the transcription factor
hypermethylatedincancer1(HIC1)viahypermethylationin
earlypreinvasivelesionsincoloncanceraswellasothertypes
of cancer [23]. Loss of HIC1 also results in additional gene
silencing events as well as downregulation of tumor protein
53 (p53).
Loss of DNA methylation results in the weakening
of transcriptional repression in normally silent regions of
the genome resulting in harmful expression of inserted or
normally silenced genes, and loss of functional stability of
chromosomes. It has been established that covalent histone
modiﬁcation is linked to DNA methylation. Cytosine methy-
lationattractsmethylatedDNA-bindingproteinsandhistone
deacetylases to methylated CpG islands during chromatin
compaction and gene silencing [32, 33]. In addition to
epigenetic modiﬁcation of transcriptional start sites, there is
evidenceformoreglobalchangesinchromatinstructure.For
instance, there is an overall decrease in the 5-methylcytosine
content of cancer genomes that is reﬂected as hyperme-
thylation in CpG islands [34]. The consistently observed
hypermethylation is due to a change in 5-methylcytosine
distributions rather than an overall increase in total amount
of methylation. It has also been observed that large stretches
of DNA can become abnormally methylated in cancer.
3.EpigeneticsofPapillary
Thyroid Carcinogenesis
Quantitative analysis of promoter hypermethylation in thy-
roid cancer has involved RASSF1A, TSHR, RARβ2, DAPK,
S100, p16, CDH1, CALCA, TIMP3, TGF-β,a n dG S T p i[ 35].
Hypermethylation of 2 or more markers (RASSF1A, TSHR,
RARβ2, DAPK, CDH1, TIMP3, and TGF-β) was detectable
in 25% of thyroid hyperplasias, 38% of adenomas, 48% of
thyroid cancers, and 100% of cell lines. Rank correlation
analysis of marker hypermethylation suggests that a subset
of the markers were hypermethylated in concert, which
may represent a thyroid-speciﬁc regulatory process [35].
Additionally, a positive correlation was observed between
BRAF mutation and RARβ2 and a negative correlation
between BRAF mutation and RASSF1A [35].
Investigation of DNA methylation in PTC has been
predominantly restricted to individual candidate tumor
suppressor genes and genes known for their role in thy-
roid function, using locus speciﬁc nonquantitative meth-
ods. BRAF, RASSFIA, TSHR, ECAD, NIS-L, ATM, DAPK,
SLC5A8, TIMP3, and RARβ2 have been analyzed for DNA




3.1. Thyroid-Stimulating Hormone Receptor (TSHR) and
Sodium Iodide Symporter (NIS). TSHR stimulates several
key steps in thyrocyte concentration of iodine, including
uptake by NIS and oxidation before incorporation into
thyroglobulin by thyroid peroxidase [36]. The methylation
status of the NIS and TSHR promoter regions are important,
because these genes are speciﬁc to the thyroid and play a
role in the uptake of iodine and normal cellular function
[37]. Promoter hypermethylation resulting in decreased
expression of TSHR and NIS may result in a decreased
ability to concentrate iodine, rendering ablative doses4 Journal of Thyroid Research
of 131I ineﬀective [37]. Promoter hypermethylation of TSHR
is reported in 34–59% [36, 37] of patients with papillary
thyroid cancer. NIS mRNA expression has been shown to
be decreased in thyroid cancers [37, 38], and this has been
proposed to be secondary to methylation of the promoter
region [32, 37]. The NIS-L region within the promoter was
shown to be hypermethylated in 22% (7/32) of patients with
papillary thyroid cancer [37]b u tw a sn o tm e t h y l a t e di n
surrounding histologically benign tissue.
3.2. E-Cadherin (ECAD). E-cadherin complexes with cat-
enins to promote Ca2+-dependent, homotypic cell-to-cell
adhesion and to establish normal epithelial tissue architec-
ture [39]. Disruption of the E-cadherin/catenin complex
contributes to tumor metastasis, and decreased expression
of E-cadherin is observed in advanced stage, poorly diﬀer-
entiated carcinomas [39]. Promoter hypermethylation has
been demonstrated in multiple human cancers, including
papillary thyroid cancer in 56% (18/32) of patients [37].
3.3.AtaxiaTelangiectasiaMutated(ATM). ATMisamember
of the phosphatidylinositol 3-kinase family of proteins that
respond to DNA damage by phosphorylating key substrates
(p53 and BRCA1) involved in DNA repair and/or cell cycle
control [40–42]. Hypermethylation of ATM promoter was
observed in 50% (16/32) of patients with papillary thyroid
cancer analyzed [37].
3.4. Apical Iodide Transporter (AIT). The thyroid apical
iodide transporter AIT encoded by the SCL5A8 gene has
been deﬁned as a sodium-coupled transporter of short-
chain fatty acid. It is thought that AIT may be involved
in the passive transport of iodide from thyrocyte to the
follicle lumen [43, 44]. Expression of SCL5A8 is decreased in
thyroid cancers compared to other iodide transporters [43]
and is expressed abundantly in colon cancer, functioning
as a tumor-suppressor gene. Silencing of SLC5A8 occurs by
promoter hypermethylation in about 50% of colon cancer
cell lines and primary colon cancers. Decreased expression
of SLC5A8 observed in classical variant of papillary thyroid
cancer is linked to hypermethylation of exon 1 of the gene
[44].
Hypermethylation occurred in 33% (76/231) of PTC
and was associated with extrathyroidal invasion (40%) and
multifocality (40%) [45]. This epigenetic event is thought
occur at a later stage in papillary thyroid cancer and speciﬁc
of the classical variant; therefore, it may be secondary to
other genetic alterations occurring selectively in the tumor
type [44]. Indeed, SLC5A8 and BRAF discriminate the
classical variant PTC, supporting the argument. In addition,
a strong association between low SLC5A8 expression and the
presence of BRAF V600E [44] or advanced clinicopathologic
features [45] suggests a link in the progression to more
aggressive papillary thyroid cancer.
3.5. The Tissue Inhibitor of Metalloproteinase 3 (TIMP3).
TIMP3 is one of 4 tissue inhibitors of metalloproteinase
thought to inhibit growth, angiogenesis, invasion, and
metastasis in several human cancers [45, 46]. TIMP3 inhibits
vascular endothelial factor-(VEGF-) mediated angiogenesis
by blocking the binding of VEGF to VEGF receptor-2,
thereby inhibiting downstream signaling and angiogenesis
[46]. Promoter hypermethylation, and downregulation of
TIMP3 expression, is observed in various human cancers
[45, 47–49] .H y p e r m e t h y l a t i o ni nP T Co c c u r r e di n5 3 %o f
tumorsanalyzedandwasassociatedwithextrathyroidalinva-
sion (38%), lymph node metastasis (43%), and multifocality
(49%).
3.6. Death-Associated Protein Kinase (DAPK). DAPK is
a calcium/calmodulin-dependent serine threonine kinase
protein with a proapoptotic, tumor-suppressor function
[45, 50]. The DAPK gene is silenced by hypermethylation
in several human cancers [45, 51, 52], including thyroid
cancer, and its expression has been shown to be a useful
m a r k e rf o rc a n c e rp r o g n o s i s[ 50]. In addition to aberrant
DNA methylation, chromatin immunoprecipitation analysis
demonstrated that histone deacetylation of the 5’ CpG island
is involved in gastrointestinal malignancies [51]. In papillary
thyroid cancer, promoter hypermethylation of DAPK was
demonstrated in 34% of PTC and was associated with tumor
multifocality (51%) [45].
3.7. Retinoic Acid Receptor-β2( R A R β2). RARβ2p l a y sa
central role in the regulation of epithelial cell growth and
tumorigenesis. Eﬀects of retinoids are mediated by nuclear
receptors, RAR-α, RAR-β,a n dR A R - γ,R X R - α,R X R - β,a n d
RXR-γ which form RXR-RAR heterodimers, that bind to
speciﬁc DNA sequences, called RAR elements. It is thought
that decreased expression of RARs may lead to resistance
to retinoid eﬀects [53]. Hypermethylation of RARβ2w a s
demonstrated in 22% of papillary thyroid cancer and was
not associated with any aggressive clinicopathologic features
[45].
4. Conclusion
With improved diagnostic techniques, endocrine tumors
are identiﬁed much more frequently than in the past. For
instance, benign parathyroid tumors occur in as many
as 2.3% of postmenopausal women [54], and primary
hyperaldosteronism may be the cause of hypertension in as
many as 4.8% of all patients with elevated blood pressure
[55]. The molecular genetics of rare inherited endocrine
tumor susceptibility syndromes, such as multiple endocrine
neoplasia (MEN) type 1 and 2, familial pheochromocytoma
syndromes, Carney complex, and Beckwith-Wiedemann
syndrome have all contributed to our understanding of
endocrine tumor development [56, 57]. Among diﬀerent
tumor types, there exist common pathways that lead to
tumorigenesis, such as inactivation of the MEN1 tumor
suppressor and activation of the RET proto-oncogene. As
in other cancers, it is believed that the vast majority of
genetic changes are somatic, that is, tumor-speciﬁc muta-
tions acquired during tumor progression [58].
Epigenetic mechanisms, especially aberrant DNA methy-
lation, very likely play an important role in papillary thyroid
tumorigenesis. Genome-wide DNA methylation studies inJournal of Thyroid Research 5
PTC provide a powerful tool to identify disease-causing
genes. Additionally, unbiased, systematic analyses of tumor
methylomes are likely to identify signaling pathways of
importance in cancer development, in general. Analyzing
epigenetic alterations in papillary thyroid cancer would
help to characterize pathogenesis and may play a critical
role in tumor classiﬁcation and diagnosis. It has recently
been shown that there are diﬀerences in global methylation
proﬁles between prognostic subsets of chronic lymphocytic
leukemia (CLL) [59]. The speciﬁc silencing of unmethylated
tumor suppressor genes was seen in the unmutated IGHV
subgroup of CLL, implying a critical role for epigenetic
changes during leukemogenesis. Interestingly, patients with
immunoglobulin heavy-chain variable gene (IGHV) unmu-
tated CLL have worse prognoses compared to CLL patients
with mutated IGHV genes [59].
Thesestudiesmayalsopavethewayfortheapplicationof
epigenetictherapeutics,bytargetedreversalofgenesilencing.
Azanucleoside drugs are demethylating agents that are cur-
rently approved for treatment of myelodyspastic syndrome
[20, 56]. These function as DNA methyltransferase enzymes
thatrequireincorporationintoDNAtobeeﬀectiveandaﬀect
the diﬀerentiated state. Other nucleoside DNA methylation
inhibitorsinclude5-ﬂuoro-2’-deoxycytidineandzebulamine
[60] which are in development. Histone deacetylases [61,
62] and histone methyltransferases are another reasonable
option for therapeutics. The histone deacetylase SAHA is
currently approved by the FDA for treatment of Tcell
lymphoma [63].
Just as multiple epigenetic events may act in con-
cert to aﬀect a single-cell pathway, it is most likely that
epigenetic therapy will involve using multiple drugs that
individually aﬀect epigenetic silencing but have synergistic
eﬀects. Proposed strategies for the FDA approved epigenetic
drugs are as single therapies or in combination as primary
or secondary treatment after neoadjuvant chemotherapy.
Lack of speciﬁcity may not pose a problem, since DNMT
inhibitors act only on dividing cells. The drugs preferentially
a c t i v a t eg e n e st h a th a v eb e c o m ea b n o r m a l l ys i l e n c e di n
cancer [64]. Moreover, the chromatin structure associated
with a pathologically silenced gene may be more susceptible
to reactivation than the highly compacted state induced by
physiological silencing [20].
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